JP2008520669A5 - - Google Patents

Download PDF

Info

Publication number
JP2008520669A5
JP2008520669A5 JP2007543135A JP2007543135A JP2008520669A5 JP 2008520669 A5 JP2008520669 A5 JP 2008520669A5 JP 2007543135 A JP2007543135 A JP 2007543135A JP 2007543135 A JP2007543135 A JP 2007543135A JP 2008520669 A5 JP2008520669 A5 JP 2008520669A5
Authority
JP
Japan
Prior art keywords
iron chelator
human
inflammation
iron
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007543135A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008520669A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/040898 external-priority patent/WO2006055412A1/en
Publication of JP2008520669A publication Critical patent/JP2008520669A/ja
Publication of JP2008520669A5 publication Critical patent/JP2008520669A5/ja
Pending legal-status Critical Current

Links

JP2007543135A 2004-11-19 2005-11-10 エリスロポエチン抵抗性を治療する方法 Pending JP2008520669A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62960604P 2004-11-19 2004-11-19
PCT/US2005/040898 WO2006055412A1 (en) 2004-11-19 2005-11-10 Methods of treating erythropoietin-resistance

Publications (2)

Publication Number Publication Date
JP2008520669A JP2008520669A (ja) 2008-06-19
JP2008520669A5 true JP2008520669A5 (enExample) 2008-12-25

Family

ID=35809986

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007543135A Pending JP2008520669A (ja) 2004-11-19 2005-11-10 エリスロポエチン抵抗性を治療する方法

Country Status (6)

Country Link
US (1) US20060128805A1 (enExample)
EP (1) EP1819334A1 (enExample)
JP (1) JP2008520669A (enExample)
AU (1) AU2005306772A1 (enExample)
CA (1) CA2587558A1 (enExample)
WO (1) WO2006055412A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083966A (en) 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
AU2003270473A1 (en) 2003-09-09 2005-04-27 University Of Florida Desferrithiocin derivatives and their use as iron chelators
JP5202299B2 (ja) 2005-04-04 2013-06-05 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド デフェリチオシンポリエーテル類似体
WO2006121995A2 (en) 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
MX2009001290A (es) * 2006-08-04 2009-02-11 Novartis Ag Tratamiento de disfusion endocrina utilizando quelantes de hierro.
BRPI0718611A2 (pt) * 2006-11-13 2014-02-25 Takeda Pharmaceuticals North America Inc Métodos para preservar a função renal utilizando inibidores da xantina oxidoredutase.
US20080132465A1 (en) * 2006-12-05 2008-06-05 Vincent Windisch Apparatus and method for isolating iron components from serum
EP2101764A4 (en) * 2006-12-12 2010-02-17 Univ Florida ACTINIDE DECORATION AGENT WITH DESFERRITHIOCIN ANALOGON
AU2008229472B2 (en) 2007-03-15 2013-03-14 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues
JPWO2010032489A1 (ja) * 2008-09-22 2012-02-09 国立大学法人旭川医科大学 鉄キレート剤及びその製造方法、並びに鉄イオンの定量・捕捉方法
WO2010045589A2 (en) * 2008-10-17 2010-04-22 The General Hospital Corporation Optimizing erythropoietin therapy
US8318484B2 (en) * 2008-11-12 2012-11-27 Tengion, Inc. Isolated renal cells and uses thereof
WO2011143292A1 (en) * 2010-05-11 2011-11-17 Ohio University Biomarkers for detecting erythropoietin use in human subjects
WO2012033941A1 (en) 2010-09-10 2012-03-15 Takeda Pharmaceuticals North America, Inc. Methods for concomitant treatment of theophylline and febuxostat
EP2664333B1 (en) 2011-01-14 2016-10-12 Disease Adsorption System Technologies Co., Ltd. Polymeric iron chelating agent
US20140073645A1 (en) 2011-03-21 2014-03-13 Vivolux Ab Treatment of Solid Tumours
WO2013090750A1 (en) 2011-12-16 2013-06-20 University Of Florida Research Foundation, Inc. Uses of 4'-desferrithiocin analogs
DK2900667T3 (da) 2012-09-21 2019-08-26 Vivolux Ab Middel og fremgangsmåde til behandling af faste tumorer
JP6838966B2 (ja) 2013-11-22 2021-03-03 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． デスフェリチオシン類似体およびその使用
JP6725515B2 (ja) * 2015-01-09 2020-07-22 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ 小分子を用いた鉄欠乏生物における生理機能の回復
AU2016255770A1 (en) 2015-04-27 2017-11-16 University Of Florida Research Foundation, Incorporated Metabolically programmed metal chelators and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8528983D0 (en) * 1985-11-25 1986-01-02 Ciba Geigy Ag Use of chelating agents

Similar Documents

Publication Publication Date Title
JP2008520669A5 (enExample)
CN104869993B (zh) 治疗阿尔茨海默病及相关疾病的组合疗法
Afshar et al. Effects of intradialytic aerobic training on sleep quality in hemodialysis patients
Kim et al. The role of NF-κB signaling pathway in polyhexamethylene guanidine phosphate induced inflammatory response in mouse macrophage RAW264. 7 cells
Herbertson et al. Anti-tumor necrosis factor-alpha prevents decreased ventricular contractility in endotoxemic pigs.
JP2010540657A5 (enExample)
JP2016513640A5 (enExample)
ATE339954T1 (de) Kombinationen von formoterol und tiotropium-salz
JP2016520573A5 (enExample)
EP2211913A4 (en) SYSTEMIC ADMINISTRATION OF CHLOROTOXIN AGENTS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS
JP2015512927A5 (enExample)
JP2018531929A (ja) Ｌ−オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる神経細胞喪失の治療および予防
JP2004517824A5 (enExample)
KR102205368B1 (ko) Fxr 작용제의 신규 요법
Buchwald et al. Bariatric surgery. A systematic review and meta-analysis
Kim et al. Combined effects of an antioxidant and caspase inhibitor on the reversal of hepatic fibrosis in rats
JP2007119497A5 (enExample)
EP1491210A4 (en) THERAPEUTIC MEDICAMENT USING ANTIBODY PRESENTING HOLES PROTEIN NANOTEHICLES AND HIGH PROTEIN NANOTEHICLES
Zhou et al. Remote ischemic preconditioning ameliorates renal fibrosis after ischemia-reperfusion injury via transforming growth factor beta1 (TGF-β1) signalling pathway in rats
CY1112440T1 (el) Απογλυκοζυλιωμενη και αποσιαλιδωμενη μακρα πεντραξινη ρτχ3
JP2011500650A5 (enExample)
Lee et al. Long-term enteral arginine supplementation in rats with intestinal ischemia and reperfusion
Liu et al. Maraviroc‐Mediated Lung Protection following Trauma‐Hemorrhagic Shock
Sedaghattalab et al. Effect of Pentoxifylline on Inflammatory Cytokines, Adequacy of Dialysis, Anemia and Biochemical Markers of Hemodialysis Patients: a Randomized Controlled Trial.
JP2019529554A5 (enExample)